ArticleAnnals of medicine and surgery (2012)2026
Tolerability of breast radiotherapy following cryoablation in the local management or palliation of breast cancer: a case series.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer is the most common malignancy among women worldwide, with surgery and radiotherapy constituting the typical standard of care. For patients who are poor surgical candidates, cryoablation offers a minimally invasive alternative with several advantages: preservation of normal tissue architecture, favorable cosmetic outcomes, and the ability to perform the procedure under local anesthesia. However, the feasibility and safety of delivering radiotherapy following cryoablation remain largely unexplored. Methods: In this retrospective single-institution case series, we report outcomes in nine women with non-operative management of breast carcinoma who underwent cryoablation followed by radiotherapy between 2018 and 2023. Tumor characteristics, reasons for inoperability, treatment parameters, and toxicity data were extracted from the electronic medical record. The primary objective was to assess the tolerability and toxicity profile of radiotherapy administered after cryoablation. Results: All nine patients completed radiotherapy without treatment breaks or dose reductions. The median tumor size was 2.3 cm (range: 0.6-4.8 cm). At a median follow-up of 30.6 months, no patient experienced skin necrosis, significant pain, or fibrosis attributable to the combined treatment. One patient developed grade 2 lymphedema; no other grade 2 or higher toxicities were observed. Although disease progression occurred in some patients due to non-definitive local intent, treatment-related toxicity remained minimal throughout the observation period. Conclusion: This case series demonstrates that radiotherapy following cryoablation is feasible, safe, and well-tolerated in patients with inoperable breast cancer, with no significant procedural complications or treatment-related toxicity. These preliminary findings support further investigation of cryoablation followed by radiotherapy as a viable treatment option for patients lacking curative surgical pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.